- Home
- IEX vs NBIX Comparison
IEX vs NBIX Comparison
Compare IEX & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IEX
- NBIX
- Stock Information
- Founded
- IEX 1987
- NBIX 1992
- Country
- IEX United States
- NBIX United States
- Employees
- IEX N/A
- NBIX N/A
- Industry
- IEX Fluid Controls
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IEX Industrials
- NBIX Health Care
- Exchange
- IEX Nasdaq
- NBIX Nasdaq
- Market Cap
- IEX 13.7B
- NBIX 12.2B
- IPO Year
- IEX 1991
- NBIX 1996
- Fundamental
- Price
- IEX $181.25
- NBIX $129.11
- Analyst Decision
- IEX Buy
- NBIX Strong Buy
- Analyst Count
- IEX 8
- NBIX 20
- Target Price
- IEX $220.14
- NBIX $163.20
- AVG Volume (30 Days)
- IEX 710.9K
- NBIX 831.5K
- Earning Date
- IEX 07-30-2025
- NBIX 07-31-2025
- Dividend Yield
- IEX 1.57%
- NBIX N/A
- EPS Growth
- IEX N/A
- NBIX N/A
- EPS
- IEX 6.30
- NBIX 2.96
- Revenue
- IEX $3,282,600,000.00
- NBIX $2,412,600,000.00
- Revenue This Year
- IEX $5.94
- NBIX $16.29
- Revenue Next Year
- IEX $4.07
- NBIX $15.08
- P/E Ratio
- IEX $28.77
- NBIX $43.66
- Revenue Growth
- IEX 1.66
- NBIX 21.73
- 52 Week Low
- IEX $153.36
- NBIX $84.23
- 52 Week High
- IEX $238.22
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- IEX 54.89
- NBIX 64.45
- Support Level
- IEX $173.76
- NBIX $125.02
- Resistance Level
- IEX $183.06
- NBIX $128.66
- Average True Range (ATR)
- IEX 3.63
- NBIX 2.80
- MACD
- IEX 0.62
- NBIX -0.12
- Stochastic Oscillator
- IEX 82.85
- NBIX 77.34
About IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. Based in Lake Forest, Illinois, Idex has manufacturing operations in over 20 countries and has over 7,000 employees. The company generated $3.3 billion in revenue in 2024.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.